Titan Pharmaceuticals (NASDAQ:TTNP) appointed Dane Hallberg to the newly created position of EVP and chief commercial officer, effective immediately, with responsibility for leading all of the company’s commercial activities.
Mr. Hallberg has 22 years of healthcare experience, including commercial leadership roles with Able Star, Sunovion Pharmaceuticals, Merck, Global Healthcare Japan, Dendrite Japan and Tierra Inc.
Most recently, he was retained by Bristol-Myers Squibb as a consultant to provide strategic guidance and project management for its global research and development, business intelligence and analytics, and health economics and outcomes research programs.
“Dane brings to Titan important experience and depth of knowledge in sales and marketing, product launch and market access as we relaunch Probuphine and work to maximize this commercial opportunity,” Titan president and CEO, Sunil Bhonsle, said in a statement.
“He was a key member of the team responsible for launching Merck’s Implanon subdermal implant contraceptive, and we are thrilled to have an executive of his caliber join our team in this important new position,” he added.
Mr. Hallberg said he has been consulting with Titan to help evaluate the market for opioid use disorder and start laying the necessary groundwork and strategies to position Titan’s Probuphine implant for success.
“Based on that early work, I am confident there is a significant and growing market for Probuphine, which has the potential to address important unmet needs in this global epidemic,” he added.
